注意力缺陷多动性障碍中的腺协同系统和核酸载体:当前发现
Sofia Corrêa Valladão1, Angela Patricia França2, Pablo Pandolfo1
1Graduate Program of Neurosciences and Department of Neurobiology, Institute of Biology, Universidade Federal Fluminense, Niterói, Brazil; Graduate Program of Physiology and Pharmacology, Biomedical Institute, Universidade Federal Fluminense, Niterói, Brazil.
Neuroscience and biobehavioral reviews
|June 16, 2024
概括
腺信号传递,特别是通过受体和平衡性核酸转运体 (ENTs),在调节涉及注意力缺陷多动性障碍 (ADHD) 的多巴胺基通路方面发挥着作用. 这篇评论探讨了腺氨酸.
科学领域:
- 神经科学是一个神经科学.
- 神经发育障碍 神经发育障碍
- 药理学 药理学是指药理学的学科.
背景情况:
- 注意缺陷多动症 (ADHD) 是一种异质的神经发育障碍,影响所有年龄段的人.
- 核心症状包括注意力不集中,过度活跃和冲动.
- ADHD的病理生理学与前额头和条形状区域的教理质,特别是多巴质,信号不平衡有关.
研究的目的:
- 审查目前对腺在调节ADHD化学,行为和认知方面的作用的理解.
- 为了检查腺对多巴胺激素信号传递在ADHD的影响.
- 探索腺受体和平衡性核酸转运体 (ENT) 在ADHD中的潜在参与.
主要方法:
- 对当前科学知识的文献综述.
- 对研究氨酸信号与多巴胺基通路相关的研究进行分析.
- 检查将腺与ADHD病理生理学联系的证据.
主要成果:
- 多巴胺基信号失衡是ADHD的核心.
- 氨酸的活性调节多巴氨基信号传递.
- 有证据表明,腺受体和平衡性核酸转运体 (ENTs) 都可能参与与ADHD相关的多巴胺变化.
结论:
- 氨酸信号传递是与ADHD相关的多巴胺基通路的关键调节器.
- 腺协同信号的改变可能与ADHD有关.
- 对腺受体和ENT在ADHD中的作用进行进一步研究是有必要的.
相关概念视频
Attention-Deficit/Hyperactivity Disorder
55
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
55
Drugs Affecting Neurotransmitter Release or Uptake
1.0K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.0K
Adrenergic Agonists: Indirect-Acting Agents
1.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.6K
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Adrenergic Neurons: Neurotransmission
3.6K
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which...
Synthesis: Catecholamine synthesis requires tyrosine, which...
3.6K
Adrenergic Agonists: Therapeutic Uses
766
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
766


